NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Shanghai Enkai Cell Technology Co., Ltd.

Shanghai Enkai Cell Technology Co., Ltd.

Private
ShanghaiHealthcare & Life Scienceshttps://nk-celltech.com/

Last Round

VC Round

Jul 9, 2025

Total Funding Raised

$15M

Company Overview

Shanghai Enkai Cell Technology Co., Ltd. is a biotechnology company that develops innovative NK (Natural Killer) cell therapies for the treatment of tumors and other major clinical diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B2C

Customer Profile

Revenue Share, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

NK cell therapyoff-the-shelf cell therapyallogeneic cell therapycancer immunotherapycell therapyclinical stage biotechoncologysynthetic immunologycell engineeringsolid tumorscryopreserved cell therapyhematologic malignanciesPBMCperipheral blood mononuclear cells

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai Enkai Cell Technology Co., Ltd. Comparables

Compare Shanghai Enkai Cell Technology Co., Ltd. with similar companies based on industry and business-model similarity.

Shanghai Enkai Cell Technology Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NK:IO
84%
Neukio Biotherapeutics
83%
Indapta Therapeutics
83%

Shanghai Enkai Cell Technology Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJul 9, 2025
VC RoundNov 22, 2024
VC RoundJun 3, 2023
Series AJul 1, 2022
AngelNov 19, 2021

Shanghai Enkai Cell Technology Co., Ltd. Investors

Notable investors and investment history

Shanghai Enkai Cell Technology Co., Ltd. investors
InvestorRounds
Beijing Fangfu Venture Capital ManagementVC Round
乔景资本 (QJ Capital)Series A
Huagai CapitalSeries A
UnifortuneSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 3, 2023

    Raised a VC Round with Beijing Fangfu Venture Capital Management.

  • Jul 1, 2022

    $15M round led by Huagai Capital

Shanghai Enkai Cell Technology Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shanghai Enkai Cell Technology Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shanghai Enkai Cell Technology Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2020
Last FundingJul 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.